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Abstract: Psoriasis is a chronic, recurrent, inflammatory disease. Recent investigations indicate an autoimmune
pathogenesis of the disease. Apoptosis plays an important role in the regulation of immune mechanisms in many
autoimmune diseases. Although CD40, CD40L, and Bcl-2 have already been studied in psoriatic skin lesions,
little is known about their circulating forms. The aim of the present study was to evaluate the serum concentra-
tions of Bcl-2, soluble CD40 and CD40L in psoriatic patients. The study was performed using ELISA kits in 39
psoriatic patients before treatment and after two weeks of topical ointment. Data was analyzed with respect to
severity of psoriasis, duration of the disease, and coexisting psoriatic arthritis. Our results revealed that serum
concentrations of soluble CD40 and CD40L before and after treatment were significantly higher (p < 0.01 and
p < 0.001) in patients with psoriasis compared to the control group. Topical treatment of psoriatic lesions with
dithranol ointment failed to decrease serum of CD40 and CD40L, which has not been described until now.
There was no significant difference in serum Bcl-2 concentration between the compared groups. We did not
find significant differences in serum concentrations of Bcl-2, CD40 or CD40L between patients with mild or
severe psoriasis, nor any correlation between disease duration and the presence of psoriatic arthritis symp-
toms. Our data indicates upregulation of the CD40/CD40L system in psoriatic patients despite topical treat-
ment and suggests their possible role in the pathogenesis of psoriasis. (Folia Histochemica et Cytobiologica
2012, Vol. 50, No. 1, 75–79)
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Introduction
Psoriasis, which affects 2–3% of the population, is
a chronic, recurrent inflammatory disease. Its main
feature is excessive proliferation of keratinocytes
and disturbances in their differentiation [1]. Recent
studies suggest an autoimmune pathogenesis of
psoriasis, with involvement of inflammatory medi-
ators derived from lymphocytes T localized in the
skin [2]. The activation of T lymphocytes depends
on cytokines released from antigen presenting cells
or due to autoimmune processes. Also, in an ex-
perimental study on psoriasis in mice, lymphocytes
T were shown to play a crucial role in initiation of
the disease [2, 3].
The protein CD40 is a member of the TNF-a re-
ceptor superfamily. CD40 is found on the antigen
presenting cells and endotheliocytes. The ligand to
CD40, i.e. CD40L (CD154) is present mainly on lym-
phocytes T CD4+ and thrombocytes. The interaction
between CD40 and its ligand drives the inflammato-
ry reaction, enhances proinflammatory cytokines
(TNF-a, IL-12) secretion, promotes T cells survival
and their differentiation to type Th1 [4]. CD40 is also
an important co-stimulating molecule necessary for
antibodies synthesis in lymphocytes B [5]. Lately,
CD40/CD40L system activation has been demonstrat-
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ed in many chronic immune diseases, such as sub-
acute skin lupus erythematosus [6], systemic lupus
erythematosus [7], dermatomyositis [8], Sjögren’s syn-
drome [9] and ulcerative colitis [10]. So far, the role
of CD40/CD40L in psoriasis has not been clarified.
In one study, an increase in serum CD40 and CD40L
in patients with psoriatic arthritis has been demon-
strated [11].
One of the main mechanisms responsible for the
elimination of excess cells is apoptosis, the pro-
grammed cell death. Decreased apoptosis has been
described as an important pathomechanism of many
immune system diseases. Uncovering the influence
of different methods of psoriasis treatment on the
apoptosis of keratinocytes and T lymphocytes is the
aim of an increasing number of studies [12]. Meth-
otrexate and UVB radiation (312 nm) have been dem-
onstrated to induce T lymphocyte apoptosis within
psoriatic lesions [13, 14].
Bcl-2 is a protooncogene protecting the cells
against apoptosis. Patients with systemic lupus erythe-
matosus [15] and Behçet disease [16] have been re-
ported to have excessive expression of Bcl-2 in serum
and lymphatic cells. To date, there have been no stud-
ies on the importance of Bcl-2 concentration in the
serum in patients with psoriasis.
We hypothesized that system CD40/CD40L is en-
hanced in psoriasis, which might reflect activation of
T lymphocytes, and at the same time, we expected
inhibition of apoptosis. The aim of the present study
was to assess the concentrations of soluble CD40, its
ligand CD40L and Bcl-2 in the serum of patients with
psoriasis of varying intensity, before treatment and
after two weeks of topical ointment use.
Material and methods
39 patients (14 women and 25 men) aged 18 to 84, (mean
48.6 ± 16.0 years) with exacerbated plaque-type psoriasis
were included in the study. Patients with other health con-
ditions that could affect Bcl-2, CD40, or CD40L serum con-
centration were excluded from the study. The duration of
psoriasis varied from two weeks to 52 months (mean: 18.4 ±
± 11.8 months). The patients were treated topically: initial-
ly with 5% salicyl ointment, followed by preparations of
cignolin (dithranol) in increasing concentrations starting
from 0.05% to 0.3%. Dithranol ointment was prepared in
the hospital pharmacy on 3% salicylic acid (as preservative)
and white vaseline as a base. The ointment was applied once
a day, for two hours. The intensity of psoriasis before and
after two weeks of treatment was assessed using the PASI
(Psoriasis Area and Severity Index) score according to Fre-
driksson and Pettersson [17], which is still widely use to es-
timate severity of the disease [18, 19]. The erythema, infil-
tration and desquamation were separately estimated on the
head, trunk, upper and lower limbs. The intensity of each
symptom was scored from 0 (no involvement) to 4 (very
severe), and the affected area of each region from 0 (no
involvement) to 6 (90–100%). The score was obtained by
multiplying the sum of intensity scores by each area score,
multiplied by constant value (head 0.1, upper limbs 0.2, trunk
0.3, lower limbs 0.4). The total PASI score is the sum of
scores of particular body parts. The PASI score varies from
0 to 72. PASI score before treatment differed from 2.8 to
27.6 (mean 10.9 ± 6.3). The control group consisted of ten
healthy subjects: eight females and two males, mean age 41±
± 16.0 years.
Blood was taken (in the morning) twice: before and af-
ter two weeks of topical treatment. After centrifugation, the
serum was stored at –80°C until analyses. The concentra-
tions of soluble CD40, CD40L and Bcl-2 in serum were
measured using commercially available ELISA kits: CD40
and CD40L (Bender MedSystems, Vienna, Austria, sensi-
tivity respectively 12 pg/ml and 0.062 ng/ml; intra-assay co-
efficience of variation [CV] 5.5% and 6.8%) and Bcl-2
(Bender MedSystems, Vienna, Austria, sensitivity 0.5 ng/ml;
CV 8.6%).
Statistical analysis was performed using Mann–Whitney
and Wilcoxon tests, p < 0.05 was regarded as significant.
The correlations between the variables were calculated us-
ing Spearman’s test.
The study was approved by the Bioethical Committee
of the Medical University of Bialystok.
Results
The concentrations of soluble CD40 and CD40L in
the studied group before treatment were significant-
ly higher than in the control group (Table 1). After
two weeks of treatment, despite a halving in the PASI
score (from 10.9 ± 6.3 to 4.2 ± 3.4), the concentra-
tions of soluble CD40 and CD40L remained signifi-
cantly higher than in the control group. Neither CD40
nor CD40L concentrations changed significantly af-
ter treatment. The concentration of Bcl-2 in the con-
trol group was higher than in psoriatic patients be-
fore treatment and after treatment (Table 1), but no
significant differences between the groups were found.
We found no significant correlations between CD40,
CD40L or Bcl-2 and severity of psoriasis, its duration
or psoriatic arthritis symptoms.
Discussion
In the present study, we demonstrate for the first time
the increase in both soluble CD40 and CD40L in pa-
tients suffering from psoriasis even without arthritis.
The concentrations were significantly higher com-
pared to the control group both before treatment and
after two weeks of topical ointment use. The higher
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concentrations of soluble CD40 and CD40L were
noted independently of the severity of skin lesions
(PASI score) and the duration of the disease.
CD40/CD40L system is an important factor in the
pathogenesis of autoimmune disorders, being a key
mediator in T and B lymphocytes cross talk [20]. CD40
is a membrane receptor appearing on B cells after stim-
ulation by cytokines derived from T lymphocytes [21].
Binding of CD40L to CD40 enables the transmission of
a co-stimulating signal, leading to enhanced prolifera-
tion, differentiation and activation of B lymphocytes, as
well as synthesis of antibodies [22]. CD40/CD40L sys-
tem has been reported to be an important factor in main-
taining the autoimmune process [23]. Enhanced expres-
sion of CD40L on T lymphocytes and the increase in its
concentration in serum was associated with an increase
in specific antibodies and the clinical activity of active
lupus erythematosus and rheumatoid arthritis [24, 25].
The presence of CD40/CD40L was shown on kerati-
nocytes both in normal skin and in psoriatic skin lesions
[26]. The enhanced expression of CD40L was associat-
ed with early stage of the disease [26].
We report significantly higher concentration of sol-
uble CD40 and CD40L in psoriatic patients compared
to the control group, which could indicate their role in
the pathogenesis of psoriasis. The results of the present
study are in accordance with those of previous reports
into psoriatic arthritis. Daoussis et al. [11] obtained sim-
ilar data, demonstrating also increased expression of
CD40L on activated T lymphocytes derived from pa-
tients with psoriatic arthritis. Additionally, the authors
observed in vitro the decrease in CD40L on T lym-
phocytes treated with cyclosporin A [11], which seems
to confirm this theory. Since several studies in recent
years have shown expression of the studied molecules
on thrombocytes and endotheliocytes and their im-
portant role in the development of atherosclerosis and
thrombosis [27, 28], it might at least partly explain
high prevalence of cardiovascular diseases in patients
suffering from psoriasis. The fact that topical treat-
ment does not lead to a decrease in CD40/CD40L
pathway activity is worrying. This might mean that
despite regression of skin lesions, the ongoing inflam-
matory process predisposes the patients with psoria-
sis (independently of intensity and duration of dis-
ease) to cardiovascular comorbidities.
This is the first report indicating that patients treat-
ed with topical ointments and untreated psoriatic
patients have similar CD40/CD40L system upregula-
tion. We propose that they need systemic treatment.
Since the number of analyzed patients in our study
was small, evaluation of a larger cohort of psoriatic
patients in future studies is desirable.
On the other hand, our finding of upregulation of
CD40/CD40L in psoriasis, together with previous re-
ports on efficacy of anti-CD40L antibodies in the
treatment of autoimmune disorders, suggests the need
to conduct such studies also in psoriasis. Toubi et al.
demonstrated the therapeutic potential of inhibiting
CD40/CD40L in lupus glomerulonephritis. Accord-
ing to them, such inhibition prevents synthesis of an-
tibodies and deposition of immune complexes in re-
nal glomeruli of patients suffering from systemic lu-
pus erythematosus [29].
Contrary to our expectations, serum concentra-
tion of Bcl-2 in psoriatic patients was not higher than
in the control group. Bcl-2 protein is a product of the
bcl-2 gene localized on the short arm of chromosome
18 and exerts an antiapoptotic role [30]. Increased
serum expression of Bcl-2 has been reported in pa-
tients with systemic lupus erythematosus [15] and in
Behçet disease [16]. So far, there has been little re-
search on Bcl-2 expression in psoriatic epidermis.
Most authors have concentrated on apoptosis of
keratynocytes, but not lymphocytes [7, 31]. Avrami-
dis et al. [32] found significant reduction in Bcl-2 and
induction of apoptosis in endothelial cells of patients
with psoriasis during etanercept treatment. Yildiz et
al. [33] observed enhanced expression of bcl-2 gene
in lymphocytes within the epidermis of psoriatic pa-
tients. The authors suggested that prolonged survival
of epidermal lymphocytes, due to their resistance
against apoptosis, could be the reason for the chron-
ic course of the disease, its recurrences and resistance
to treatment. The decreased Bcl-2 expression in lym-
phocytes within psoriatic lesions after topical treat-
ment with calcipotriol seems to confirm this theory,
although calcipotriol appears to have its effect main-
Table 1. Concentrations of CD40, CD40L and Bcl-2 in serum of the control group and patients suffering from psoriasis
before and after treatment. Data is given as median (full range). Significant differences compared to the control group are
shown as **p < 0.01; ***p < 0.001 within a row
Control group Psoriasis
Before treatment After treatment
SCD40 [pg/ml] 33 (12–48) 55 (18–108)** 57 (19–101)**
SCD40L [ng/ml] 2.2 (0.6–7.2) 10.4 (2.9–19.4)*** 10.2 (4.9–19.7)***
Bcl-2 [ng/ml] 15.0 (7.0–76.5) 11.1 (5.6–20.2) 11.1 (6.7–23.8)
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ly on keratinocytes rather than lymphocytes [34]. Our
results do not show any significant difference in se-
rum concentration of Bcl-2 in patients with psoriasis,
either before or after topical treatment, compared to
the control group. A low level of Bcl-2 is an unex-
pected finding and may suggest that Bcl-2 does not
play a major contributory role in the antiapoptotic
mechanisms that are proposed to be important in
psoriasis. Nevertheless, there remains the possibility
that other antiapoptotic proteins might participate in
the hypothetical blockage of the apoptotic response
in psoriatic lymphocytes. Further studies are neces-
sary to clarify this issue.
In conclusion, in this study we have not observed
any significant difference either in Bcl-2 concentra-
tion in the serum of psoriatic patients, nor an effect
of the topical treatment on its expression.
The results of the present study indicate activa-
tion of CD40/CD40L signaling pathway in patients
suffering from psoriasis independently of the severi-
ty of skin lesions, duration of the disease or topical
treatment. This seems to confirm the role of CD40/
/CD40L interaction in the pathogenesis of psoriasis.
Unfortunately, we also certified a lack of topical treat-
ment effect on the immune mechanisms involved in
the disease, which indicates the need for systemic
treatment. Further investigations are needed to con-
firm their role in an increased risk of cardiovascular
comorbidities among those patients.
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